Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
May 05, 2016
- Translarna&#8482 net sales of $18.9M representing 49% sequential growth -
- Full-year net sales on track to meet guidance of $65M to $85M -
- Proof of concept achieved in second SMA compound, RG7916 and clinical study in SMA patients planned for 2H of 2016 -
Additional Formats
Apr 26, 2016
SOUTH PLAINFIELD, N.J. , April 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that Tuyen Ong , M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research .
Additional Formats
Apr 22, 2016
SOUTH PLAINFIELD, N.J. , April 22, 2016 /PRNewswire/ -- PTC Therapeutics , Inc. ( NASDAQ : PTCT) today announced that on April 22, 2016 it approved non-statutory stock options to purchase an aggregate of 26,000 shares of its common stock to 4 new employees.
Additional Formats
Apr 21, 2016
SOUTH PLAINFIELD, N.J. , April 21, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Thursday, May 5, 2016 at
Additional Formats
Apr 15, 2016
-Positive Recommendation Enables Reimbursed Patient Access to First Approved Therapy to Treat Underlying Cause of Devastating Rare Disease-
Additional Formats
Mar 23, 2016
SOUTH PLAINFIELD, N.J. , March 23, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the company is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S.  This reduction is part of PTC's program intended to
Additional Formats
Mar 14, 2016
SOUTH PLAINFIELD, N.J. , March 14, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that data from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)
Additional Formats
Mar 14, 2016
SOUTH PLAINFIELD, N.J. , March 14, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study for review by Health Canada as part of the New Drug Submission (NDS) for Translarna™
Additional Formats
Mar 02, 2016
SOUTH PLAINFIELD, N.J. , March 2, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that on February 25, 2016 it approved non-statutory stock options to purchase an aggregate of 29,500 shares of its common stock to 12 new employees.
Additional Formats
Feb 29, 2016
- Refuse to File letter received from FDA regarding Translarna™ (ataluren) for nmDMD -
- Successful first year ex-U.S. launch with 2015 Translarna net sales of $33.7M -
- Translarna European regulatory submissions for DMD and CF under review by the CHMP -
- Strong balance sheet with $339M in cash at year-end -
Additional Formats